Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
TOKYO and CAMBRIDGE, Mass., Aug 22, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc.announced today that the humanized amyloid-beta(Aβ) monoclonal antibody “Leqembi®” (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatmentof […]




